Sipagladenant

pharmacological · nervous · Oral

Sipagladenant. Investigational adenosine A2A receptor antagonist and inverse agonist studied in clinical trials in Parkinson disease.

Investigational adenosine A2A receptor antagonist and inverse agonist studied in clinical trials in Parkinson disease.

PK: PMID:36683291 reports mean terminal half-lives spanning 18.4–43.1 hours across single-dose groups, rather than one representative value. PMID:38178727 models an active metabolite; its contribution requires review. DOSE: PMID:37948832 studied 3 or 6 mg orally once daily for 12 weeks in early Parkinson disease; these are investigational trial arms.

Sources: PMID:37948832, PMID:36683291, PMID:38178727